Long-Term Efficacy of Guselkumab in an Adolescent Hidradenitis Suppurativa Patients: A Case Report

References

• Chiricozzi A, Veraldi S, Fabbrocini G, et al. The Hidradenitis Suppurativa (HS) ”multidisciplinary unit”: a rationale and practical proposal for an organised clinical approach. Eur J Dermatol. 2018;28(2):274–275. doi:10.1684/ejd.2018.3254
   PubMedGoogle Scholar
• Martora F, Martora L, Fabbrocini G, Marasca C. A case of pemphigus vulgaris and hidradenitis suppurativa: may systemic steroids be considered in the standard management of hidradenitis suppurativa? Skin Appendage Disord. 2022;8(3):265–268.
   PubMedGoogle Scholar
• Goldburg SR, Strober BE, Payette MJ. Hidradenitis suppurativa: epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol. 2020;82(5):1045–1058.
   PubMed Web of Science ®Google Scholar
• Stephan C, Kurban M, Abbas O. Reply to: “Hidradenitis suppurativa: epidemiology, clinical presentation, and pathogenesis”. J Am Acad Dermatol. 2020;83(5):e371.
   PubMed Web of Science ®Google Scholar
• Nguyen TV, Damiani G, Orenstein LAV, Hamzavi I, Jemec GB. Hidradenitis suppurativa: an update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life. J Eur Acad Dermatol Venereol. 2021;35(1):50–61.
   PubMed Web of Science ®Google Scholar
• Martora F, Marasca C, Battista T, Fabbrocini G, Ruggiero A. Management of patients with hidradenitis suppurativa during COVID-19 vaccination: an experience from southern Italy. Comment on: evaluating the safety and efficacy of COVID-19 vaccination in patients with hidradenitis suppurativa. Clinical Experimental Dermatol. 2022;47(11):2026–2028. doi:10.1111/ced.15306
   PubMed Web of Science ®Google Scholar
• Kimball AB, Okun MM, Williams DA, et al. Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med. 2016;375(5):422–434. doi:10.1056/NEJMoa1504370
   PubMed Web of Science ®Google Scholar
• Jemec GBE, Okun MM, Forman SB, et al. Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the Phase III randomized placebo-controlled PIONEER trials. Br J Dermatol. 2019;181(5):967–975. doi:10.1111/bjd.17919
   PubMed Web of Science ®Google Scholar
• Zouboulis CC, Okun MM, Prens EP, et al. Long-term Adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study. J Am Acad Dermatol. 2019;80(1):60–69.e2. doi:10.1016/j.jaad.2018.05.040
   PubMed Web of Science ®Google Scholar
• Martora F, Megna M, Battista T, et al. Adalimumab, ustekinumab, and secukinumab in the management of hidradenitis suppurativa: a review of the real-life experience. Clin CosmetInvestig Dermatol. 2023;16:135–148.
   Google Scholar
• Kimball AB, Jemec GBE, Alavi A, et al. Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials. Lancet. 2023;401(10378):747–761. doi:10.1016/S0140-6736(23)00022-3
   PubMed Web of Science ®Google Scholar
• Martora F, Scalvenzi M, Battista T, et al. Guselkumab, risankizumab, and tildrakizumab in the management of hidradenitis suppurativa: a review of existing trials and real-life data. Clin Cosmet Invest Dermatol. 2023;16:2525–2536. doi:10.2147/CCID.S418748
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Potestio L, Martora F, Villani A, Comune R, Megna M. Bimekizumab treatment in patients with moderate to severe plaque psoriasis: a drug safety evaluation [published online ahead of print. Expert Opin Drug Saf. 2023;2023:1–8.
   Google Scholar
• Glatt S, Jemec GBE, Forman S, et al. Efficacy and safety of bimekizumab in moderate to severe hidradenitis suppurativa: a phase 2, double-blind, placebo-controlled randomized clinical trial [published correction appears in JAMA Dermatol. JAMA Dermatol. 2021;157(11):1279–1288. doi:10.1001/jamadermatol.2021.2905
   PubMed Web of Science ®Google Scholar
• Martora F, Scalvenzi M, Ruggiero A, Potestio L, Battista T, Megna M. Hidradenitis suppurativa and jak inhibitors: a review of the published literature. Medicina. 2023;59(4):801. doi:10.3390/medicina59040801
   PubMedGoogle Scholar
• Ruggiero A, Picone V, Martora F, Fabbrocini G, Megna M. Guselkumab, risankizumab, and tildrakizumab in the management of psoriasis: a review of the real-world evidence. Clin Cosmet Invest Dermatol. 2022;15:1649–1658. doi:10.2147/CCID.S364640
   PubMed Web of Science ®Google Scholar
• Vu A, Ulschmid C, Gordon KB. Anti-IL 23 biologics for the treatment of plaque psoriasis. Expert opin biol ther. 2022;22(12):1489–1502. doi:10.1080/14712598.2022.2132143
   PubMed Web of Science ®Google Scholar
• Megna M, Tommasino N, Potestio L, et al. Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study. J Dermatol Treat. 2022;33(6):2813–2820.
   PubMed Web of Science ®Google Scholar
• Reich K, Armstrong AW, Foley P, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the Phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017;76(3):418–431. doi:10.1016/j.jaad.2016.11.042
   PubMed Web of Science ®Google Scholar
• Reich K, Armstrong AW, Langley RG, et al. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Lancet. 2019;394(10201):831–839. doi:10.1016/S0140-6736(19)31773-8
   PubMed Web of Science ®Google Scholar
• Dudink K, Bouwman K, Chen Y, et al. Guselkumab for hidradenitis suppurativa: a Phase II, open-label, mode-of-action study. Br J Dermatol. 2023;188(5):601–609. doi:10.1093/bjd/ljad010
   PubMed Web of Science ®Google Scholar
• Kimball AB, Podda M, Alavi A, et al. Guselkumab for the treatment of patients with moderate-to-severe hidradenitis suppurativa: a phase 2 randomized Study [published online ahead of print, 2023 Jun 14]. J Eur Acad Dermatol Venereol. 2023. doi:10.1111/jdv.19252
   PubMedGoogle Scholar
• Casseres RG, Kahn JS, Her MJ, Rosmarin D. Guselkumab in the treatment of hidradenitis suppurativa: a retrospective chart review. J Am Acad Dermatol. 2019;81(1):265–267.
   PubMed Web of Science ®Google Scholar
• Montero-Vilchez T, Martinez-Lopez A, Salvador-Rodriguez L, Arias-Santiago S, Molina-Leyva A. The use of guselkumab 100 mg every 4 weeks on patients with hidradenitis suppurativa and a literature review. Dermatol Ther. 2020;33(3):1.
   Web of Science ®Google Scholar
• Kovacs M, Podda M. Guselkumab in the treatment of severe hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2019;33(3):e140–e141.
   PubMed Web of Science ®Google Scholar
• Garcia-Melendo C, Vilarrasa E, Cubiró X, Bittencourt F, Puig L. Sequential paradoxical psoriasiform reaction and sacroiliitis following adalimumab treatment of hidradenitis suppurativa, successfully treated with guselkumab. Dermatol Ther. 2020;33(6):e14180. doi:10.1111/dth.14180
   PubMed Web of Science ®Google Scholar
• Martora F, Fabbrocini G, Marasca C, Battista T, Megna M. Paradoxical hidradenitis suppurativa induced by Adalimumab biosimilar successfully treated with guselkumab in a patient with psoriasis. Comment on ‘Paradoxical hidradenitis suppurativa due to anti-interleukin-1 agents for mevalonate kinase deficiency successfully treated with the addition of ustekinumab’. Clin Exp Dermatol. 2023;48(6):701–703.
   PubMedGoogle Scholar
• Ruggiero A, Martora F, Picone V, Marano L, Fabbrocini G, Marasca C. Paradoxical hidradenitis suppurativa during biologic therapy, an emerging challenge: a systematic review. Bio Med. 2022;10(2):455. doi:10.3390/biomedicines10020455
   Google Scholar
• Repetto F, Roccuzzo G, Burzi L, et al. Drug survival of anti interleukin-17 and interleukin −23 agents after adalimumab failure in hidradenitis suppurativa: a pilot study. Acta Derm Venereol. 2023;103(5278):1.
   Google Scholar
• Martora F, Marasca C, Picone V, Fornaro L, Megna M, Fabbrocini G. How adalimumab impacts antibiotic prescriptions in patients affected by hidradenitis suppurativa: a 1-year prospective study and retrospective analysis. J Clin Med. 2023;12(3):837.
   PubMed Web of Science ®Google Scholar
• Burzi L, Repetto F, Ramondetta A, et al. Guselkumab in the treatment of severe hidradenitis suppurativa, a promising role? Dermatol Ther. 2021;34(3):e14930.
   PubMed Web of Science ®Google Scholar
• Berman HS, Villa NM, Shi VY, Hsiao JL. Guselkumab in the treatment of concomitant hidradenitis suppurativa, psoriasis, and Crohn’s disease. J Dermatol Treatment. 2021;32(2):261–263. doi:10.1080/09546634.2019.1654067
   PubMed Web of Science ®Google Scholar
• Jørgensen AR, Holm JG, Thomsen SF. Guselkumab for hidradenitis suppurativa in a patient with concomitant crohn’s disease: report and systematic literature review of effectiveness and safety. Clinical Case Reports. 2020;8(12):2874–2877. doi:10.1002/ccr3.3090
   PubMedGoogle Scholar
• Čagalj A M, Marinović B, BukvićMokos Z. New and emerging targeted therapies for hidradenitis suppurativa. Int J Mol Sci. 2022;23(7):3753. doi:10.3390/ijms23073753
   PubMed Web of Science ®Google Scholar
• Martora F, Marasca C, Fabbrocini G, Ruggiero A. Strategies adopted in a southern Italian referral centre to reduce adalimumab discontinuation: comment on can we increase the drug survival time of biologic therapies in hidradenitis suppurativa?’. Clin Exp Dermatol. 2022;47(10):1864–1865.
   PubMed Web of Science ®Google Scholar
• Martora F, Picone V, Fabbrocini G, Marasca C. Hidradenitis suppurativa flares following COVID-19 vaccination: a case series. JAAD case reports. 2022;23:42–45. doi:10.1016/j.jdcr.2022.03.008
   PubMedGoogle Scholar